korrents

korrents · piece

Manufacturing requirements are killing cell and gene therapy

Ruxandra Teslo · 10 Jun 2026

Read the piece on writingruxandrabio.com ↗

2 korrents from this piece ↓

Ruxandra Teslo did not write this page.

Every claim below was made in this piece, quoted word for word and numbered in the order the piece makes them, so you can read it there rather than take our word for it. The sentence above each quote is our reading of the claim, not their wording. Each quote was checked against a stored copy of the page at build time; where the two differ, the quote is the fact.

  1. Our reading

    Manufacturing and batch-release requirements, not biology, are what kill most promising cell and gene therapies.

    Mental modelBottlenecks

    Their wordsExcessive manufacturing requirements are a pervasive problem, especially in the field of cell and gene therapy and they are killing countless of promising medicines before they ever reach patients.

  2. Our reading

    Investment will keep draining out of cell and gene therapy until manufacturing and regulatory risk become possible to underwrite.

    Mental modelBottlenecks

    Their wordsUntil manufacturing and regulatory risks become easier to underwrite, capital will keep drifting away from one of the most promising technologies of the last century.

Keep reading

The other pieces are the ones whose claims are worded most like this one's. That measures language, not agreement: they may argue the opposite.